Basic information |
Metabolite name | Cholesterol |
HMDB0000067 | |
C00187 | |
5997 | |
Synonyms | Total cholesterol |
No. of studies | 25 |
Relationship between Cholesterol and depression (count: 25) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M025 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Down |
Study M040 | Type1 | MDD group vs. control group | Plasma | Human | Down |
Study M071 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Up |
Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Down |
Study M092 | Type1 | LPS group vs. control group | Prefrontal cortex | CD-1 mouse | Down |
Study M1075 | Type1 | CSDS group vs. control group | Frontal cortex | C57BL/6J mouse | Down |
Study M1075 | Type1 | CSDS group vs. control group | Serum | C57BL/6J mouse | Down |
Study M127 | Type1 | FSL group vs. control group | Hypothalamus | Sprague-Dawley rat | Up |
Study M128 | Type1 | CMS group vs. control group | Medial prefrontal cortex | Sprague-Dawley rat | Down |
Study M131 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M207 | Type1 | depressed group vs. control group | Serum | Kunming mouse | Down |
Study M209 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
Study M463 | Type3 | venlafaxine group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
Study M610 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
Study M611 | Type1 | LPS group vs. control group | Heart | Sprague-Dawley rat | Unknown |
Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
Study M611 | Type1 | LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Unknown |
Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Up |
Study M738 | Type1 | CMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
Study M738 | Type2 | CMS + Xiaoyaosan group vs. CMS group | Hippocampus | Sprague-Dawley rat | Up |
Study M744 | Type1 | CUS transplant group vs. control transplant group | Hippocampus | Sprague-Dawley rat | Down |
Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
Study M775 | Type1 | prenatal stress group vs. control group | Brain | Swiss Webster mouse | Up |
Study M894 | Type1 | electromagnetic field exposure group vs. control group | Serum | C57BL/6J mouse | Up |
Study M894 | Type2 | electromagnetic field exposure + heat acclimation group vs. electromagnetic field exposure group | Serum | C57BL/6J mouse | Down |
Study M910 | Type1 | depression group vs. control group | Dorsolateral prefrontal cortex | Human | Down |
Study M910 | Type1 | depression group vs. control group | Cerebellum | Human | Down |
Study M935 | Type2 | chronic social isolation + tianeptine group vs. chronic social isolation group | Hippocampus | Wistar rat | Up |
Study M935 | Type4 | chronic social isolation + tianeptine group vs. chronic social isolation + tianeptine resilient group | Hippocampus | Wistar rat | Up |
Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Down |
Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Down |
Study M955 | Type2 | CUMS + deoiled and dechlorogenic acid-enriched sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |
Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Down |